Despite its associated benefits which include better long-term pulmonary and neurodevelopmental outcome, the use of caffeine for apnoea of prematurity (AoP) has been limited in low- and middle-income
Supporting datasets for the publication "Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling".
Advances reported over the last few years and the increasing availability of protein crystal structure data have greatly improved structure-based druggability approaches. However, in practice, nearly
